Retatrutide: The Triple-Agonist That Could Redefine Obesity Treatment

Retatrutide (LY3437943) is a first-in-class triple incretin receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. The GLP-1 and GIP components reduce appetite and improve glucose metabolism, similar to tirzepatide. The novel addition of glucagon receptor agonism is hypothesized to increase energy expenditure, enhance hepatic fat oxidation, and promote thermogenesis. This triple mechanism may explain the unprecedented weight loss seen in early trials, potentially exceeding what dual agonists achieve.

Retatrutide (development code LY3437943) is an investigational medication being developed by Eli Lilly that represents the next evolution in incretin-based therapy. While tirzepatide targets two receptors (GLP-1 and GIP), retatrutide targets three: GLP-1, GIP, and glucagon. This triple-agonist approach is designed to combine the appetite suppression and metabolic benefits of GLP-1/GIP with the energy-expenditure and fat-burning effects of glucagon receptor activation. In Phase 2 clinical trials, retatrutide produced the largest weight loss ever reported for a pharmaceutical intervention, with some dose groups approaching 25% body weight reduction in under a year.

The Phase 2 trial of retatrutide, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity (without diabetes) and randomized them to various doses of retatrutide or placebo for 48 weeks. The 12 mg dose group achieved a mean weight loss of 24.2%, surpassing the 22.5% seen with tirzepatide 15 mg in SURMOUNT-1 (over 72 weeks). Notably, the weight-loss curve at 48 weeks had not yet plateaued, suggesting that longer treatment could produce even greater results. In the diabetes cohort (36-week study), the 12 mg dose achieved 16.9% weight loss alongside substantial HbA1c reduction. Perhaps most striking was the liver fat data: retatrutide reduced hepatic fat by over 80% in participants with fatty liver disease, with most achieving complete resolution.

The innovation in retatrutide is the addition of glucagon receptor agonism to the GLP-1/GIP backbone. Glucagon, traditionally viewed as a counter-regulatory hormone to insulin, has potent effects on energy metabolism. Glucagon receptor activation stimulates hepatic fat oxidation (burning of fat in the liver), increases energy expenditure through thermogenesis, and may reduce hepatic lipid accumulation. These effects complement the appetite suppression provided by GLP-1 and GIP. The concern with glucagon is its glucose-raising effect, but in retatrutide, this is counterbalanced by the insulin-stimulating effects of GLP-1 and GIP, resulting in net glucose improvement rather than hyperglycemia.

Eli Lilly launched the Phase 3 TRIUMPH clinical trial program for retatrutide in late 2023. The program includes multiple large-scale trials evaluating retatrutide for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). If Phase 3 results confirm Phase 2 findings, an FDA submission could occur in 2026, with potential approval in 2027 or 2028. Eli Lilly is also studying retatrutide for obstructive sleep apnea in the setting of obesity. The company has invested heavily in manufacturing capacity in anticipation of potential approval.

Retatrutide is not yet available and cannot be prescribed. Patients interested in this medication should watch for Phase 3 trial results and potential FDA approval in the coming years. In the meantime, tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) are the available FDA-approved options. The development of retatrutide signals a broader trend toward multi-target medications that address obesity through multiple physiological mechanisms simultaneously. Patients should be cautious of any claims about retatrutide availability from compounding pharmacies or online sources, as the drug is not approved for any use and is not commercially manufactured.